Scilex Holding (SCLX) Change in Receivables (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Receivables of -$4.6 million for Q1 2026, up 70.95% year-over-year from -$2.7 million in Q1 2025, and down 792.32% quarter-over-quarter from $664000.0 in Q4 2025.
Scilex Holding (SCLX) Change in Receivables (2022 - 2026) Analysis & Trends
Scilex Holding's Change in Receivables history runs 5 years deep, the most recent figure standing at -$4.6 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 70.95% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$2.6 million (up 44.15% YoY), while the FY2025 annual figure was -$13.8 million, down 320.79% from the prior year.
- Change in Receivables for Q1 2026 stood at -$4.6 million, down from $664000.0 in the prior quarter.
- The five-year high for Change in Receivables was $18.2 million in Q4 2023, with the low at -$15.8 million in Q1 2025.
- The 5-year median for Change in Receivables is $664000.0 (2025), against an average of $480117.6.
- Peak annual rise in Change in Receivables reached 1605.74% in 2023, while the deepest fall reached 807.75% in 2023.
- Scilex Holding's Change in Receivables stood at $3.8 million in 2022, then jumped by 382.96% to $18.2 million in 2023, then slumped by 55.43% to $8.1 million in 2024, then slumped by 91.8% to $664000.0 in 2025, then sank by 792.32% to -$4.6 million in 2026.
- Business Quant data shows SCLX's Change in Receivables at -$4.6 million in Q1 2026, $664000.0 in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn | -4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.60 Mn |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | 664,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | -4.83 Mn |
| Sep 30, 2025 | -4.83 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | -15.82 Mn |
| Mar 31, 2025 | -15.82 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Sep 30, 2024 | -5.24 Mn |
| Sep 30, 2024 | -5.24 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Dec 31, 2023 | 18.17 Mn |
| Dec 31, 2023 | 18.17 Mn |